These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 15503324)

  • 1. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer.
    Preda A; Novikov V; Möglich M; Turetschek K; Shames DM; Brasch RC; Cavagna FM; Roberts TP
    J Magn Reson Imaging; 2004 Nov; 20(5):865-73. PubMed ID: 15503324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights.
    Turetschek K; Preda A; Novikov V; Brasch RC; Weinmann HJ; Wunderbaldinger P; Roberts TP
    J Magn Reson Imaging; 2004 Jul; 20(1):138-44. PubMed ID: 15221819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats.
    Fournier LS; Novikov V; Lucidi V; Fu Y; Miller T; Floyd E; Shames DM; Brasch RC
    Radiology; 2007 Apr; 243(1):105-11. PubMed ID: 17329684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological animal models in the experimental evaluation of tumour microvasculature with magnetic resonance imaging.
    Faccioli N; Marzola P; Boschi F; Sbarbati A; D'Onofrio M; Pozzi Mucelli R
    Radiol Med; 2007 Apr; 112(3):319-28. PubMed ID: 17440699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation.
    Daldrup-Link HE; Okuhata Y; Wolfe A; Srivastav S; Øie S; Ferrara N; Cohen RL; Shames DM; Brasch RC
    Microcirculation; 2004; 11(5):387-96. PubMed ID: 15280064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.
    Cyran CC; Fu Y; Rogut V; Chaopathomkul B; Wendland MF; Shames DM; Brasch RC
    Acad Radiol; 2013 Oct; 20(10):1256-63. PubMed ID: 24029057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrast-enhanced MRI of murine sponge model for progressive angiogenesis assessed with gadoteridol (ProHance) and gadocoletic acid trisodium salt (B22956/1).
    Ramponi S; Rebaudengo C; Cabella C; Grotti A; Vultaggio S; Aime S; Morisetti A; Lorusso V
    J Magn Reson Imaging; 2008 Apr; 27(4):872-80. PubMed ID: 18383249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
    Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
    Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantifying angiogenesis in VEGF-enhanced tissue-engineered bladder constructs by dynamic contrast-enhanced MRI using contrast agents of different molecular weights.
    Cheng HL; Wallis C; Shou Z; Farhat WA
    J Magn Reson Imaging; 2007 Jan; 25(1):137-45. PubMed ID: 17139634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DCE-MRI using small-molecular and albumin-binding contrast agents in experimental carcinomas with different stromal content.
    Farace P; Merigo F; Fiorini S; Nicolato E; Tambalo S; Daducci A; Degrassi A; Sbarbati A; Rubello D; Marzola P
    Eur J Radiol; 2011 Apr; 78(1):52-9. PubMed ID: 19443159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model.
    Turetschek K; Preda A; Floyd E; Shames DM; Novikov V; Roberts TP; Wood JM; Fu Y; Carter WO; Brasch RC
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):448-55. PubMed ID: 12722742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of tamoxifen in an experimental model of breast tumor studied by dynamic contrast-enhanced magnetic resonance imaging and different contrast agents.
    Marzola P; Ramponi S; Nicolato E; Lovati E; Sandri M; Calderan L; Crescimanno C; Merigo F; Sbarbati A; Grotti A; Vultaggio S; Cavagna F; Lorusso V; Osculati F
    Invest Radiol; 2005 Jul; 40(7):421-9. PubMed ID: 15973133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance imaging enhancement of normal tissues and tumors using macromolecular Gd-based cascade polymer contrast agents: preclinical evaluations.
    Raatschen HJ; Fu Y; Shames DM; Wendland MF; Brasch RC
    Invest Radiol; 2006 Dec; 41(12):860-7. PubMed ID: 17099424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis.
    Bäuerle T; Bartling S; Berger M; Schmitt-Gräff A; Hilbig H; Kauczor HU; Delorme S; Kiessling F
    Eur J Radiol; 2010 Feb; 73(2):280-7. PubMed ID: 19070445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-invasive quantification of anti-angiogenic therapy by contrast-enhanced MRI in experimental pancreatic cancer.
    Raatschen HJ; Fischer S; Zsivcsec B; Schoenfeld CO; Hotz B; Buhr HJ; Hotz HG
    Acta Radiol; 2014 Mar; 55(2):131-9. PubMed ID: 23892234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
    Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
    Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance imaging assays for dimethyl sulfoxide effect on cancer vasculature.
    Cyran CC; Sennino B; Chaopathomkul B; Fu Y; Rogut V; Shames DM; Wendland MF; McDonald DM; Brasch RC
    Invest Radiol; 2008 May; 43(5):298-305. PubMed ID: 18424950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI.
    Li KL; Wilmes LJ; Henry RG; Pallavicini MG; Park JW; Hu-Lowe DD; McShane TM; Shalinsky DR; Fu YJ; Brasch RC; Hylton NM
    J Magn Reson Imaging; 2005 Oct; 22(4):511-9. PubMed ID: 16161072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation of prostate cancer from normal prostate tissue in an animal model: conventional MRI and dynamic contrast-enhanced MRI.
    Gemeinhardt O; Lüdemann L; Prochnow D; Abramjuk C; Taupitz M; Hamm B; Beyersdorff D
    Rofo; 2005 Jul; 177(7):935-9. PubMed ID: 15973594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues.
    Cyran CC; Fu Y; Raatschen HJ; Rogut V; Chaopathomkul B; Shames DM; Wendland MF; Yeh BM; Brasch RC
    J Magn Reson Imaging; 2008 Mar; 27(3):581-9. PubMed ID: 18219614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.